A simple stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of diclazuril (DIC) in the presence of its induced degradation products. The drug was subjected to stress stability study including acidic, alkaline, photolytic, thermal and oxidative stress conditions, and the stressed samples were analyzed by the proposed method. The developed method utilized a C 18 column (250 3 4.6 mm, i.d., 5 mm) in an isocratic separation mode with mobile phase consisting of acetonitrile and 0.2% phosphoric acid at a flow rate of 1.2 mL/min with UVdetection at 275 nm. The proposed method was validated according to the International Conference on Harmonization guidelines. The method was applied in short term and accelerated stability studies for determination of the DIC in bulk powder and in its pharmaceutical formulation.
Introduction

Diclazuril (DIC) is (RS)-(4-chlorophenyl)
-(3,5-dioxo-4,5-dihydro-1,2,4-triazin-2(3H)-yl)phenyl]acetonitrile ( Figure 1 ). It is a benzene acetonitrile anti-protozoal agent (1) . It is a broad-spectrum anticoccidial with proven efficacy against intestinal Eimeria species in avian coccidiosis (2) , intestinal and hepatic coccidiosis in rabbits (3) and toxoplasmosis in mice (4) . DIC is intended for use in major poultry species including broiler chickens and turkeys. It is also used in minor bird species, rabbits and lambs. It is administered as a medicated feed premix at a recommended dose of 1 ppm (5) .
The literature survey reveals several analytical methods for quantification of DIC in chicken tissues and in animal feed by high-performance liquid chromatography (HPLC) methods with ultraviolet detection (6) (7) (8) . DIC was determined in poultry tissues and other biological matrices by LC-tandem mass spectrometry (9 -12) .
There is no reported stability-indicating LC method for the estimation of DIC in its pure form or in its pharmaceutical formulation. Therefore, attempts were made in this study to develop a fast, sensitive, selective and stability-indicating reversed-phase HPLC method for its determination. The proposed method is able to separate DIC from its impurities, degradation products and placebo components. The developed method was validated with respect to specificity, linearity, limit of detection (LOD) and limit of quantification (LOQ), precision, accuracy and robustness. Forced degradation studies were performed on the placebo and drug product. The developed method separates all degradation products from DIC and exhibits stability-indicating nature. The developed method was validated in accordance with the established International Conference on Harmonization (ICH) guidelines.
Experimental
Chemicals and reagents DIC standard was obtained from Janssen Animal Health (Beerse, Belgium). Its potency was found to be 99.84% (n ¼ 6) according to the official British Pharmacopoeia (BP) method (1). Acetonitrile and dimethylformamide (DMF) were HPLC grade (Sigma-Aldrich, Germany). Phosphoric acid was purchased (Scharlau, Spain). Double distilled water was used throughout the experiment (Aquatron, UK). Sodium hydroxide (NaOH), hydrochloric acid (HCl) and hydrogen peroxide (H 2 O 2 ) were from ADWIC, El-Nasr Pharm. Co. (Cairo, Egypt). Chicox powder to be mixed with feed (claimed to contain 5 g of DIC, colloidal silicon dioxide 10 g and lactose monohydrate 985 g per 1 kg powder) was manufactured by Marcyrl Pharmaceutical Company (Cairo, Egypt).
HPLC instrumentation conditions
Agilent LC system (Bo¨blingen, Germany) consisted of a quaternary pumping system (Agilent model G1311A), a UV variable wavelength detector (model G1315D, Agilent) and an autosampler (model G13329A) equipped with a degasser (G1322A, Agilent).
Stationary phase consisted of a symmetry C 18 analytical column (250 Â 4.6 mm, i.d., 5 mm) (Waters, Milford, MA, USA). The column temperature was maintained at 358C. The mobile phase was acetonitrile -0.2% aqueous phosphoric acid (70 : 30, v/v). Elution was isocratic at a flow rate of 1.2 mL/min. The mobile phases were filtered through a 0.45-mm Millipore membrane filter (Billerica, MA, USA) and degassed for 15 min in an ultrasonic bath prior to use. UV detection was done at 275 nm. The samples were filtered also through a 0.45-mm membrane filter, and the injection volume was10 mL. For analysis of forced degradation samples, the photodiode array detector was used in scan mode with a scan range of 200 -400 nm. The peak homogeneity was expressed in terms of peak purity and was obtained directly from the spectral analysis report.
Standard and sample solutions
Standard stock solution DIC standard stock solution (1 mg/mL) was prepared by transferring 50 mg of DIC standard into a 50-mL volumetric flask containing 25 mL DMF and sonicated for 10 min, and then, the volume was completed with DMF.
Working solutions
Serial dilutions were prepared from this stock solution in the mobile phase to obtain DIC solutions having a concentration range of 1 -200 mg/mL.
Analysis of pharmaceutical formulation A mass of 2 g of Chicox powder (equivalent to 10 mg DIC) was transferred into a 50-mL volumetric flask containing 25 mL of DMF and sonicated for 10 min, and then, the volume was completed with the same solvent. A volume of 5 mL of this solution was transferred into a 10-mL volumetric flask and diluted to volume with mobile phase to obtain DIC solution having a concentration of 100 mg/mL.
Procedure for forced degradation study of drug substance Forced degradation of DIC and the drug product was carried out under thermolytic, photolytic, acid/base hydrolytic and oxidative stress conditions.
Acid degradation
A mass of 10 mg of DIC was dissolved in 10 mL DMF, and then, 10 mL of 0.1 N HCl was added. The solution was kept at room temperature for 24 h. The solution was neutralized with 10 mL of 0.1 N NaOH. Then, the volume was made up to 100 mL with the mobile phase.
Alkaline degradation
Accurately 10 mg of DIC was dissolved in 10 mL DMF, and then, 10 mL of 0.1 N NaOH was added. The solution was kept at room temperature for 24 h. The solution was neutralized with 10 mL of 0.1 N HCl. Then, the volume was made up to 100 mL with the mobile phase.
Oxidative degradation Accurately 10 mg of DIC was dissolved in 10 mL DMF. A volume of 10 mL of 3% H 2 O 2 was added, and then, the solution was kept at room temperature for 24 h. The volume was made up to 100 mL with the mobile phase.
Thermal degradation
Accurately 10 mg of drug substance was kept at 808C for 24 h. Then, the solution was prepared in the mobile phase to obtain 100 mg/mL of DIC.
UV degradations
About 10 mg of drug substance was exposed to short-wave UV (254 nm) and long-wave UV (366 nm) light for 24 h. The solution was prepared to achieve 100 mg/mL of DIC.
Forced degradation of Chicox powder Different masses, each of 2 g, of Chicox powder (equivalent to 10 mg DIC) were subjected, separately, to acidic, basic, oxidative, thermolytic and photolytic stress conditions (as described under 'Procedure for forced degradation study of drug substance'). Then, each solution was prepared to achieve 100 mg/mL of DIC.
Method validation
Serial concentrations of DIC standard solutions in the range of 1 -200 mg/mL were chromatographed using the described chromatographic conditions to determine the linearity of the method. The calibration graph was obtained by plotting the peak area against the concentration of the drug, and the regression parameters were computed. The previously mentioned procedure was repeated for the determination of different concentrations of the studied drug to determine the accuracy and precision of the method. Degraded and unknown samples were assayed by the proposed method. The peak purity values were obtained using a photodiode array detector to test the specificity of the method. The robustness of the method was investigated by analysis of samples under a variety of experimental conditions such as small changes in mobile phase ratio, flow rate, column temperature and changing the column using a Zorbax w C18 analytical column (250 Â 4.6 mm, i.d., 5 mm).
Results
Chromatographic separation
Separation of DIC from its degradation products was achieved by applying the chromatographic conditions described in the experimental part. Figure 2 shows the chromatogram of standard DIC solution. The average retention time of DIC was 4.2 + 0.2 min. Figure 3 shows chromatogram of acid hydrolysis degradation. Figure 4 shows the chromatogram of base hydrolysis degradation. Figure 5 shows chromatograms of oxidative degradation.
Method validation
The applied method was linear in the range of 1-200 mg/mL of DIC. The regression characteristics of the proposed method are shown in Table I . Accuracy was determined by calculating the percentage recovery values that are shown in Table I . The precision of the method was studied by determining the concentration of DIC six times. The results of the precision study indicate that the method is reliable (Table I ). The intermediate precision (inter-day precision) of the method was also evaluated, and the results are shown in Table I .
Assay DIC in Chicox powder
The chromatogram of the test product (Chicox powder) is shown in Figure 6 . It was similar to that of pure DIC with no extra peaks of additives. The assay results of DIC in Chicox powder to be mixed with feed were estimated. The percentage recovery was found to be 100.55 + 0.64.
Discussion
Optimization of chromatographic conditions
The primary target in developing this stability-indicating HPLC method is to determine DIC quantitatively in the presence of its expected degradants or excipients. The method is valid to determine DIC in its pharmaceutical formulation and in stability studies. The proposed method achieved resolution between DIC and its degradation products. It was applied for short-term accelerated stability studies. To develop a stability-indicating method, different stationary phases (C 18 , CN) and different mobile phases (containing buffers such as phosphate, ammonium acetate and ammonium formate) with different pH and organic modifier (acetonitrile) were used.
Resolution between DIC and its degradation products was investigated using different C 18 and cyano columns, but unsatisfactory resolution was obtained. Symmetry w C 18 column showed better performance as compared with other columns. The analyte showed symmetrical peak shape, less tailing and optimum resolution. DIC and its degradation products are well separated in the optimized conditions.
Forced degradation study
A target degradation of 20 -80% was suggested for the establishing stability-indicating nature of the assay method as even intermediate degradation products should not interfere with any stage of drug analysis (13) . Although conditions used for forced degradation were attenuated to achieve degradation in the range of 20 -80%, this could not be achieved in all degradation conditions even after exposure for prolonged duration. Chromatographic peak purity data were obtained from the spectral analysis report, and a peak purity value of .990 indicates a homogeneous peak. The peak purity values indicate homogeneous peaks and thus establishing the specificity of the assay method. Figure 2 shows the chromatogram of standard DIC solution. DIC was subjected to different stress conditions. Acidic degradation occurred to DIC but to a less extent by 0.1 N HCl (Figure 3) . DIC contains two amide links that are easily broken under alkaline stress conditions. That may explain the massive degradation of DIC by NaOH, as shown in Figure 4 . Oxidative degradation of DIC occurred and degradants were separated from DIC by the proposed method ( Figure 5 ). DIC was stable to thermolytic and photolytic degradation pathways, and the obtained chromatograms were typical to that of untreated DIC. The stress conditions used were realistic to achieve the expected degradation products that may be formed during storage of DIC on the long run. More drastic conditions were excluded to avoid over stressing of DIC and to avoid formation of unusual and unexpected degradants. The ICH guidelines do not specify certain conditions for accelerated degradation but recommend 0.1-1 N acid or alkali for hydrolysis without specifying the degradation conditions as they differ from a drug moiety to other.
System suitability parameters were tested by calculating the capacity factor, tailing factor, the sensitivity factor and resolution. The results of system suitability testing are listed in Table II .
The chromatographic systems described in this work allow complete baseline separation of DIC from its degradation products. No other co-eluting peaks were found with the main DIC peak. One sample can be chromatographed in 6 min. The method could be used as a stability-indicating assay for determination of DIC in the presence of degradation products.
Method Validation
Linearity
Linearity of the method was tested by injecting serial concentrations of DIC standard solutions in triplicate. The calibration graph was obtained by plotting peak area against the concentration of the drug. The method was linear in the range of 1 -200 mg/mL of DIC.
Specificity
The peak purity values were carried out using a photodiode array detector. The peak purity was .997 for drug substance and drug products at 275 nm, which shows that the peaks of analytes were pure and that formulation excipients and degradation were not interfering with the analyte peak. The described method was validated with respect to specificity, linearity, system suitability, accuracy, robustness, LOD, LOQ and intermediate precision.
Accuracy
The recovery experiments were performed by adding known amounts of the drug in the placebo. The recovery was performed at three levels: 80, 100 and 120% of the claimed amount 100 mg/ mL of DIC. Three samples were prepared for each recovery level. The solutions were then analyzed, and the percentage recoveries were calculated from the calibration curve.
Robustness
The robustness of a method is the ability to remain unaffected by small changes in parameters. To determine robustness of the method, experimental conditions were purposely altered, and chromatographic resolution between DIC and its degradants was evaluated.
The flow rate of the mobile phase was 1.2 mL/min. To study the effect of flow rate, it was changed to 1.1 and 1.3 mL/min. The effect of column temperature on resolution was studied at 33 and 378C instead of 358C. Small change in the mobile phase ratio was done changing from acetonitrile -0.2% aqueous phosphoric acid (70 : 30 to 68 : 32 or 72 : 28, v/v), and different C 18 columns were used (Zorbax w ). The robustness of the method was assured by the small change in the retention time, but the DIC peak retained its shape and resolution.
Limit of detection and limit of quantification
The LOD and LOQ for DIC were determined at a signal-to-noise ratio of 3 : 1 and 10 : 1, respectively, by injecting a series of dilute solutions with known concentrations (14) . The LOD and LOQ were 0.25 and 0.66 mg/mL, respectively, for 10-mL injection volume. The LOQ was validated by analyzing a number of samples equal to the quantitation limit with acceptable recoveries and precision.
Assay of DIC in Chicox powder
The assay results of DIC in Chicox powder to be mixed with feed were comparable with the value of label claimed. The percentage recovery of five determinations was found to be 100.55 + 0.64 (Table III) . The obtained results indicate the suitability of the method for routine analysis of DIC in Chicox powder. The smaller the value, the higher the column efficiency a Resolution was calculated with respect to the least resolved peak of the alkaline degradate as shown in Figure 4 . 
Conclusion
The developed method is a stability-indicating method while separating degradation products from the main peak. No co-eluting peak with DIC main peak and the method is specific for the estimation of DIC in the presence of its degradation products. The method has a linear response in the stated range with a good accuracy and precision. The proposed method can be conveniently used by quality control departments to determine the assay of DIC in Chicox powder to be mixed with feed and also stability samples.
